Search Results

Aurigene will provide cell therapy discovery services to Edity to support the latter’s clinical development

Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley

Aurigene.AI is an end-to-end solution for small molecule drug discovery combining AI and ML capabilities with Aurigene’s core expertise in synthesizing and testing the molecules in vitro and in vivo. The platform consists of a meticulously curated database that serves as training data. The modular platform allows users flexibility in selecting suitable AI models from a set of generative, predictive, and computational algorithms. It utilizes an iterative ML process for ratio

Aurigene Pharmaceutical Services Ltd. (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DEL technologies, entered into a strategic partnership.

AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, announced the opening of its new antibody discovery technologies research center.

The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx’s pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory diseases and improve global access to innovative medicines.

Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organization and a step-down subsidiary of Dr. Reddy’s Laboratories

Waypoint Bio Launches with $14.5M to Turbocharge Drug Discovery using in vivo Spatial Pooled Screening Technology.

Novotech, the global full-service clinical Contract Research Organization that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, announced it has signed a Memorandum of Understanding with Hong Kong-Shenzhen Innovation and Technology Park Limited.

AbTherx, Inc. and Single Cell Technology, Inc. announced that AbTherx selected Single Cell for its first antibody discovery campaigns.